Nationwide surveillance in Taiwan of the in-vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Enterobacteriaceae

详细信息    查看全文

• 作者：Chin-Te Lu ; Yin-Ching Chuang ; Wu Sun ; Yung-Ching Liu ; Yu-Jen Cheng ; Po-Liang Lu ; Chih-Ming Chen ; Gwo-Jong Hsu ; Tsrang-Neng Jang ; Chun-Ming Lee ; Ping-Cherng Chiang ; Zhi-Yuan Shi ; Lih-Shinn Wang ; Hsiang-Chi Kung ; Hsiu-Chen Lin ; Chun-Hsing Liao ; Jien-Wei Liu ; Cheng-Hua Huang ; Shih-Ming Tsao ; Po-Ren Hsu
• 关键词：Tigecycline ; Extended-spectrum beta-lactamase ; Etest ; Broth microdilution ; Taiwan ; Enterobacteriaceae
• 刊名：International Journal of Antimicrobial Agents
• 出版年：2008
• 出版时间：November 2008
• 年：2008
• 卷：32
• 期：Supplement 3
• 页码：S179-S183
• 全文大小：151 K

文摘

ABSTRACT

Tigecycline In-vitro Surveillance in Taiwan (TIST), initiated in 2006, is a nationwide surveillance programme designed to monitor longitudinally the in-vitro activity of tigecycline against commonly encountered resistant bacteria. This study compared the in-vitro activity of tigecycline against clinical isolates of resistant Gram-negative bacteria determined by the broth microdilution and Etest methods. A total of 622 isolates were collected from patients treated at 20 teaching hospitals. Tigecycline had excellent in-vitro activity against extended-spectrum β-lactamase (ESBL)-producing Escherichia coli (N = 275) with MIC₉₀ 0.5 μg/mL and a 99.6 % susceptibility rate, and also against ESBL-producing Klebsiella pneumoniae (N = 324) with MIC₉₀ 2 μg/mL and a 98.5 % susceptibility rate. For ESBL-producing Proteus mirabilis (N = 15) the MIC₉₀ was 4 μg/mL with a 73.3 % susceptibility rate. For ESBL-producing Klebsiella oxytoca (N = 8) the MIC₅₀ and MIC₉₀ were 0.5 and 1 μg/mL, respectively, with a 100 % susceptibility rate. Limited agreement (<80 % ) was found between the broth microdilution and the Etest methods when determining the in-vitro activity of tigecycline against ESBL- producing K. pneumoniae and K. oxytoca.